VEGF and HER2 — Drug Target
All drugs that target VEGF and HER2 — marketed and clinical-stage. Includes 1 drug classes acting on this target.
Drug classes
Bispecific monoclonal antibody
Phase 3 pipeline (1)
- VB4-845 Injection · Qilu Pharmaceutical Co., Ltd. · Bispecific monoclonal antibody · Oncology
VB4-845 is an anti-VEGF/HER2 bispecific antibody that simultaneously targets vascular endothelial growth factor and human epidermal growth factor receptor 2 to inhibit tumor angiogenesis and block HER2-driven proliferation.